Insight

Photo taken from Fred Saad/X

Sep 26, 2024, 12:37

Exclusive Interview With Fred Saad

MediaMedic shared on LinkedIn:

“Exclusive Insights on mHSPC Treatment: Interview with Fred Saad.

In a recent Media Medic interview, our colleague El Bachir Mourabit had the privilege to speak with Dr. Fred Saad about breakthrough advancements in metastatic hormone-sensitive prostate cancer (mHSPC) treatment.

Dr. Saad emphasized the importance of combining androgen deprivation therapy (ADT) with ARPIs like apalutamide, enzalutamide, or abiraterone for improved survival.

He also shared promising results from the Phase 3 ARINOTE study, showcasing darolutamide with ADT as a safe and effective option, especially for patients who may not tolerate chemotherapy.”

Source: MediaMedic/LinkedIn

abiraterone androgen deprivation therapy apalutamide cancer chemotherapy darolutamide El Bachir Mourabit Enzalutamide Fred Saad MediaMedic mHSPC treatment OncoDaily Oncology

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage